West Pharmaceutical Services, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
West is a global manufacturer of containment and delivery systems, packaging components, drug-delivery products, analytical services, and contract-manufactured devices for pharmaceutical, biologic, diagnostic, and medical-device customers. The report covers the unaudited three months ended March 31, 2023, compared with the same period in 2022.
The business is organized into Proprietary Products and Contract-Manufactured Products. Q1 2023 sales were approximately 44% Americas, 47% Europe, Middle East and Africa, and 9% Asia Pacific.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Net sales | $716.6 million | $720.0 million | Down 0.5%; up 2.3% excluding currency |
| Gross profit | $271.3 million | $284.6 million | Down 4.7% |
| Gross margin | 37.9% | 39.5% | Down 1.6 percentage points |
| Operating profit | $155.3 million | $189.7 million | Down 18.1% |
| Operating margin | 21.7% | 26.3% | Down 4.6 percentage points |
| Adjusted operating profit | $164.9 million | $189.9 million | Down 13.2% |
| Adjusted operating margin | 23.0% | 26.4% | Down 3.4 percentage points |
| Net income | $140.0 million | $173.8 million | Down 19.4% |
| Diluted EPS | $1.85 | $2.29 | Down 19.2% |
| Operating cash flow | $138.1 million | $151.2 million | Down $13.1 million |
Interest income increased to $4.8 million from $0.3 million, while net interest expense remained $2.2 million. The effective tax rate increased to 14.9% from 11.3%, primarily because a prior-year state tax valuation allowance reversal did not recur and geographic earnings mix changed.
At March 31, 2023, cash and cash equivalents were $886.3 million, working capital was $1.402 billion, and total debt was $208.3 million. The company had no borrowings under its $500.0 million revolving credit facility and reported $497.6 million of available capacity, including outstanding letters of credit. Capital expenditures were $82.1 million, compared with $65.8 million in Q1 2022.
Material changes versus the prior comparable period
- Consolidated sales declined modestly on a reported basis because of a $20.1 million unfavorable foreign-currency translation impact. Organic sales increased 2.3%.
- Proprietary Products sales declined 3.0% reported and 0.1% organically. COVID-related sales declined by approximately $88 million, partially offset by pricing.
- Contract-Manufactured Products sales increased 12.5% reported and 14.4% organically, driven primarily by injection-related device components and price increases.
- Gross margin declined because of the loss of higher-margin COVID-related sales, inflation in transportation and compensation costs, and additional plant spending. Contract-Manufactured Products margin fell to 17.6% from 20.1% due to inflation and unfavorable product mix.
- Research and development expense increased 17.1% to $17.1 million, including additional work on glass systems.
- Other expense was $12.9 million versus other income of $3.1 million in the prior year. Q1 2023 included $11.3 million of asset impairments, including a $9.4 million impairment related to a manufacturing facility planned for sale.
- Operating cash flow decreased, while capital spending increased to support manufacturing capacity. Financing cash use declined primarily because share repurchases were lower than in Q1 2022.
- Share repurchases totaled $60.1 million for 183,360 shares at an average price of $327.90. A new $1.0 billion authorization was approved in February 2023, with $939.9 million remaining at March 31.
Guidance, outlook, management commentary, risks and unusual items
No formal full-year revenue or earnings guidance is provided in the filing text. Management expects its restructuring plan, approved in December 2022 and scheduled for implementation over up to twelve months, to require approximately $25 million to $27 million of charges and generate annualized savings of $22 million to $24 million.
The planned sale of a Proprietary Products manufacturing facility was expected to close in Q2 2023. The related $9.4 million impairment was recorded in Q1. The company also reported $24.7 million of remaining restructuring obligations at March 31, 2023.
Management cited elevated raw-material costs, inflation, supply-chain constraints, foreign-currency volatility, and uncertainty related to the Russia-Ukraine conflict. The conflict had not materially affected the company through March 31, 2023, but escalation could increase energy, supply-chain, and operating costs.
Other risks include customer demand and inventory changes, competition, reliance on third-party and single-source suppliers, execution of price increases, product and regulatory approval timing, availability of skilled labor, commodity prices, foreign-exchange movements, cybersecurity or operational disruptions, and healthcare legislation. The company added a risk concerning potential bank failures, restricted access to deposits or credit, and broader financial-system liquidity pressures.
The company was in compliance with all debt covenants and reported no material changes to commitments or contingencies. Management stated that cash, operating cash generation, and revolver availability should be adequate for foreseeable liquidity needs. No material off-balance-sheet financing arrangements were reported beyond ordinary-course purchase obligations and letters of credit.
Most important facts for investors to verify
- Whether the decline in COVID-related sales stabilizes and whether organic growth in Contract-Manufactured Products offsets weakness in Proprietary Products.
- Whether pricing, productivity, and restructuring savings recover margin pressure from inflation, product mix, and higher plant costs.
- The timing and proceeds of the planned manufacturing-facility sale and whether additional impairment or restructuring charges arise.
- Progress toward the stated $22 million to $24 million of annualized restructuring savings and the remaining $25 million to $27 million charge outlook.
- Capital-expenditure requirements, inventory growth, operating cash conversion, and continued use of the $1.0 billion share-repurchase authorization.
- Foreign-exchange, commodity, supply-chain, customer-concentration, regulatory, and financial-institution liquidity risks.